VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer

Completed · Phase 2

Conditions studied: Lung Cancer

In brief

RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well VNP40101M works in treating patients with recurrent or refractory locally advanced or metastatic small cell lung cancer.

Key facts

Study ID

NCT00282022

Run by

Vion Pharmaceuticals

People needed

87

Starts

2005-09-01

Last updated by the study team

2013-11-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles, California, United States
• Yale Cancer Center — New Haven, Connecticut, United States
• Veterans Affairs Medical Center - West Haven — West Haven, Connecticut, United States
• Helen F. Graham Cancer Center at Christiana Hospital — Newark, Delaware, United States
• Albert Einstein Cancer Center at Albert Einstein College of Medicine — The Bronx, New York, United States
• Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio, United States
• Kimmel Cancer Center at Thomas Jefferson University - Philadelphia — Philadelphia, Pennsylvania, United States
• Sarah Cannon Cancer Center at Centennial Medical Center — Nashville, Tennessee, United States
• M. D. Anderson Cancer Center at University of Texas — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.